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As with any emerging health concern, feasible measures 
for reducing exposure should be explored where possible. 
This could be achieved by limiting the noise output of the 
devices but allowing sufficient volume for use in environ-
ments with high background noise. Clinicians should 
advise current users to avoid listening to personal music 
players at maximum volume. Regarding other safety con-
cerns, it would be prudent to advise removing earphones 
while driving and performing other safety sensitive tasks.
More comprehensive and ongoing surveys of the hearing 
health of young people are needed, both to clarify the role 
of personal music players in hearing loss, and to develop 
evidence based guidelines for safe usage. As clinicians 
come to grips with how electronic devices that afford so 
much pleasure may also produce harm, personal music 
players provide a reminder that our hunger for new tech-
nology should be accompanied by equally vigorous efforts 
to understand and manage the health consequences of 
changing lifestyles.
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Ten years of the Global Alliance for Vaccines and 
Immunisation
Successes of immunisation are tempered by slow progress in strengthening 
health systems
The Global Alliance for Vaccines and Immunisation (GAVI), 
now known as the GAVI Alliance, was created in 2000 to 
increase the availability and use of immunisation in poor 
countries. GAVI’s launch, which was made possible by a 
start-up grant of $750m (£486m; €550m) from the Gates 
Foundation, was part of broader efforts by world leaders to 
strengthen public health action across the globe in the late 
1990s. Nine million children die in the developing world 
annually, two million from diseases for which vaccines are 
available. Over the past decade, GAVI has immunised 256 
million children and, in doing so, has averted five million 
deaths.1
For many, the measurable achievements of GAVI make it 
the flagship among a flood of global public-private partner-
ships in health. The alliance has achieved this by playing 
a “market shaping role”—for example, by consolidating 
populations into larger markets and exerting downward 
pressure on prices (as it did for hepatitis B and diphtheria-
pertussis-tetanus vaccines) through its purchasing power. 
It has also politicised vaccines, in the best possible sense, 
and made world leaders recognise the importance of immu-
nisation. The results are impressive, especially to donors 
seeking good news stories to leverage support for their 
funding decisions—the number of countries where polio 
is endemic has been reduced from 125 to four; 233 million 
additional children have been immunised against hepatitis 
B; and the prospects of childhood vaccines for malaria and 
meningitis, and other new products are exciting. The recent 
announcement of an additional $10bn of funding from the 
Gates Foundation to support vaccine research, develop-
ment, and delivery is seen as a major vote of confidence 
for GAVI’s work.2
Yet the alliance has not been immune to criticism. 
Although it is generally seen as an effective manager of an 
ambitious grant making enterprise, changes to its govern-
ance have been necessary to improve the quality and appro-
priateness of its funded activities. Of particular concern have 
been a lack of clarity about the relative roles of various part-
ner institutions, the need for better technical support for 
countries applying for GAVI grants, and too little meaning-
ful participation in priority setting by recipient governments. 
This last problem has led to familiar accusations of donor 
driven agendas and even the foisting of vaccines on recipi-
ent countries.3 GAVI’s governance structure was streamlined 
in 2008 when the alliance’s two distinct decision making 
bodies—the GAVI Alliance board and the funding board—
merged, with the aim of combining “the best of multilateral 
and public sector values and experiences with the added 
value of private sector dynamics and challenge.”4
What is less clear is how this will ensure that the needs 
of recipient countries are taken into account. This raises 
difficult questions about GAVI’s raison d’être, which—given 
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a single minded focus on child immunisation—reignites 
longstanding tensions between vertical and horizontal 
approaches to health development.5 GAVI claims that 
immunisation is “one of the most efficient, successful 
and cost-effective health investments in history.”6 Others 
 disagree, warning that insufficient attention to strengthen-
ing health systems skews priorities, diverts resources from 
other health needs, and creates unsustainable activities.7
GAVI sought to reconcile the disease and systems 
approaches by launching the Health Systems Strength-
ening (HSS) “investment window” in 2006. The goal of 
strengthening the capacity of health systems to deliver 
high quality immunisation services, and the principles 
behind achieving this (that they should be country driven, 
aligned with national planning and budget cycles, innova-
tive, catalytic, and above all tackle unmet needs in existing 
support) have been widely supported. However, independ-
ent evaluations suggest much work remains to be done to 
realise this ambition. Lack of resources has not been the 
problem: HSS has been financed by the GAVI Fund and 
International Finance Facility for Immunisation (IFFIm), 
and there are reports of a planned HSS “financing plat-
form” by the World Bank, Global Fund, and GAVI.8 The 
enduring challenge has been the lack of an agreed strat-
egy—notably, what exactly a health system is and what 
strengthening actions work best.9 Evidence suggests that 
GAVI grants have largely been used for downstream short 
term fixes, rather than the upstream long term structural 
reforms really needed to strengthen health systems.10-12 
More operational research is urgently needed to under-
stand how GAVI might best support HSS for child immu-
nisation that could, in turn, create a kind of “herd effect” 
in generating wider benefits for a broader range of health 
development needs.
The world is a better place for millions of children 
because of the increased rates of immunisation that 
GAVI has achieved over the past 10 years. The challenge 
is to ensure that these children go on to live their lives 
meaningfully and with dignity. This will require equi-
table access to the full range of basic needs, and to this 
end, the world still has a long way to go.
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community acquired pneumonia
New guidelines focus on management in primary care
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Community acquired pneumonia is an important cause 
of morbidity and mortality, yet it is often misdiagnosed 
and improperly treated. Guidelines have been produced 
by several societies, and these have helped to organise 
the approach to this disease; highlighted areas that need 
further research; and reduced length of stay, mortality, 
and costs in patients admitted to hospital.1-5
Recently a summary of the British Thoracic Society 
(BTS) guidelines for community acquired pneumonia 
was published that focuses on management in primary 
care.3 6 The guidelines are a manageable length for gen-
eral practitioners and have important educational and 
quality assurance functions.
Some of the BTS recommendations however, differ 
from those of the Infectious Diseases Society of America 
(IDSA) and American Thoracic Society (ATS) guidelines. 
Although the practice of medicine and the prevalence of 
certain pathogens may differ between the United King-
dom and United States, certain problems are common on 
both sides of the Atlantic. The diagnosis of pneumonia is 
one of them.
There are two key factors in the diagnosis of commu-
nity acquired pneumonia. The first is whether the patient 
 actually has pneumonia and the second is identification of 
the pathogen responsible.
Several infectious and non-infectious entities can be 
confused with pneumonia. The BTS summary statement 
claims that the typical patient history of cough, fever, and 
dyspnoea with chest pain and lung crackles on examina-
tion cannot reliably discriminate community acquired 
pneumonia from other acute lower respiratory tract infec-
tions. They also state that various prediction rules have 
generally “shown the need for confirmatory radiographic 
evidence.” Despite this, there seems to be undue reliance 
on the clinical diagnosis of community acquired pneumo-
nia and a routine chest radiograph is not recommended. It 
is suggested instead that a chest radiograph may be done 
if the diagnosis is in doubt. This is a circular argument 
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